Capricor Therapeutics (CAPR, Financial) maintains its "Buy" rating as per the latest report from HC Wainwright & Co., dated July 11, 2025. The analyst responsible for the update, Joseph Pantginis, has made adjustments to the price target for the stock.
The price target for Capricor Therapeutics (CAPR, Financial) has been lowered from a previous target of USD 77.00 to a new target of USD 24.00. This adjustment reflects a significant change, representing a percentage decrease of approximately 68.83%.
Despite the adjustment in the price target, the retention of the "Buy" rating indicates continued confidence from HC Wainwright & Co. in the potential of Capricor Therapeutics (CAPR, Financial) in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Capricor Therapeutics Inc (CAPR, Financial) is $34.60 with a high estimate of $77.00 and a low estimate of $20.00. The average target implies an upside of 346.46% from the current price of $7.75. More detailed estimate data can be found on the Capricor Therapeutics Inc (CAPR) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Capricor Therapeutics Inc's (CAPR, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Capricor Therapeutics Inc (CAPR, Financial) in one year is $11.23, suggesting a upside of 44.91% from the current price of $7.7499. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Capricor Therapeutics Inc (CAPR) Summary page.
